ORAI1 and melanoma: More recently, Stanisz et al. reported SOCE in both primary (SK-MEL-28) and metastatic (SK-MEL-5, WM3734) melanoma cells, although either pharmacological SOCE inhibition or knockdown of Orai1 and STIM2 resulted in faster growth, linked to malignancy (Stanisz et al., 2014).